PTC Therapeutics (NASDAQ:PTCT) Issues Quarterly Earnings Results

PTC Therapeutics (NASDAQ:PTCT) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($1.46), Zacks reports. The business had revenue of $164.68 million for the quarter, compared to analysts’ expectations of $281.45 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm’s quarterly revenue was down 22.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.85) EPS.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Sephience global launch is off to a strong start with broad uptake across ages and centers, generating approximately $92M in Q4 and $111M of revenue since launch in 2025.
• PTC provided 2026 product revenue guidance of $700M–$800M (majority from Sephience) and OpEx guidance of $680M–$720M, positioning the company to potentially reach cash-flow breakeven in 2026.
• PTC monetized the remainder of its Evrysdi royalty to Royalty Pharma for $240M upfront (plus up to $60M in sales milestones) and retains a possible $150M Roche sales milestone, but the transaction changes future royalty cash dynamics despite continuing to show Evrysdi on the financial statements.
• Votoplam (Huntington’s) advanced toward registrational development after an FDA end-of-phase-2 meeting; Novartis will start the phase 3 INVEST‑HD trial in H1 2026 with an interim analysis that could support an accelerated approval pathway.
• Vatiquinone received a CRL and FDA indicated an additional study will be required (likely an open‑label single‑arm study using a natural history comparator), delaying a clear path to resubmission while PTC and FDA align on protocol in Q2 2026.

PTC Therapeutics Stock Performance

NASDAQ PTCT opened at $69.90 on Friday. The company has a market cap of $5.61 billion, a PE ratio of 8.17 and a beta of 0.48. The firm’s 50 day moving average price is $75.01 and its 200-day moving average price is $67.78. PTC Therapeutics has a 52-week low of $35.95 and a 52-week high of $87.50.

Wall Street Analysts Forecast Growth

PTCT has been the subject of a number of recent analyst reports. Citigroup boosted their price objective on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Royal Bank Of Canada downgraded PTC Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their target price for the stock from $82.00 to $91.00 in a research report on Monday, December 1st. The Goldman Sachs Group upped their price target on shares of PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of PTC Therapeutics in a report on Monday, December 29th. Finally, Wells Fargo & Company raised their target price on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Ten analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $80.67.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full‑year 2025 product and royalty revenue came in at $831M, exceeding company guidance, showing underlying sales resilience. PR Newswire Release
• Positive Sentiment: Sephience (sepiapterin), launched in 2H‑2025, showed strong uptake with Q4 revenue of $92M and $111M for full year 2025—this product momentum is a key upside driver if growth continues. PR Newswire Release
• Positive Sentiment: PTC ended 2025 with approximately $1.95B in cash, which provides a sizable runway to fund launches, R&D and potential business development. PR Newswire Release
• Neutral Sentiment: Company filed Q4 results and held a conference call; investors should listen for management’s details on Sephience rollout pace, expense outlook and timing of pipeline catalysts. Q4 Press Release / Slides
• Negative Sentiment: Q4 EPS missed badly: loss of $1.67 vs. consensus loss near $0.37 (Zacks reports similar misses), and revenue of $164.7M fell well short of the ~$281M estimate—these misses are the primary driver of the stock decline. Zacks: Q4 Loss & Revenue Miss
• Negative Sentiment: FY‑2026 revenue guidance was set at $700–$800M versus consensus near $974M, signaling a significant step‑down in near‑term top‑line expectations and increasing downside risk to estimates. PR Newswire Release
• Negative Sentiment: Market media flagged further investor concern after the company’s Translarna NDA withdrawal raised questions about regulatory/pathway risk for that program. Yahoo Finance: Translarna NDA Withdrawal
• Negative Sentiment: Insider selling: VP Mark Boulding sold ~5,894 shares over Feb. 17–18 at ~\$69.3/share; while not uncommon, the disclosed sales add to near‑term negative sentiment. SEC Form 4

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, CAO Christine Marie Utter sold 1,034 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $76.45, for a total transaction of $79,049.30. Following the sale, the chief accounting officer owned 72,693 shares of the company’s stock, valued at approximately $5,557,379.85. This trade represents a 1.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew B. Klein sold 2,514 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $76.45, for a total value of $192,195.30. Following the completion of the transaction, the chief executive officer directly owned 394,453 shares of the company’s stock, valued at approximately $30,155,931.85. The trade was a 0.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 276,765 shares of company stock valued at $21,903,948 over the last 90 days. Insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

Several hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its holdings in shares of PTC Therapeutics by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company’s stock valued at $301,856,000 after buying an additional 224,481 shares in the last quarter. Janus Henderson Group PLC lifted its position in PTC Therapeutics by 28.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company’s stock valued at $368,587,000 after acquiring an additional 1,077,776 shares during the last quarter. State Street Corp boosted its stake in PTC Therapeutics by 34.2% in the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company’s stock valued at $319,497,000 after acquiring an additional 1,071,343 shares in the last quarter. Toronto Dominion Bank grew its holdings in PTC Therapeutics by 27.5% in the fourth quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company’s stock worth $314,339,000 after purchasing an additional 891,690 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in PTC Therapeutics by 16.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,023,091 shares of the biopharmaceutical company’s stock worth $77,714,000 after purchasing an additional 146,682 shares during the last quarter.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.